Biopharmaceutical company Soligenix Inc (Nasdaq:SNGX) revealed on Thursday that it expects to receive the patent from the US Patent Office titled "Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity" on 9 April 2019.
This new patent, which has been assigned the number #10,253,068, claims composition of matter for novel innate defence regulator (IDR) analogs, expanding patent protection to diverse analog structures. Therapeutic use claims in oral mucositis, colitis and infectious disease, both alone and in conjunction with antibiotics, will also issue.
According to the company, Dusquetide (the active ingredient in SGX942) is a novel, first-in-class IDR. It modulates the response of the innate immune system in response to various stimuli, including infection, tissue damage and inflammation. IDRs have no direct antibiotic activity but, by modulating the host's innate immune system responses, increase survival after infections caused by a broad range of bacterial Gram-negative and Gram-positive pathogens.
SGX942 demonstrated positive results in a Phase 2 study in the treatment of oral mucositis in head and neck cancer (HNC) patients. In addition to the oral mucositis findings, an increased incidence of "complete response" of tumour at the one-month and 12-month follow-up visits were observed. Decreases in infection rate and an increase in the 12-month survival rate were observed, stated the company.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007